ES2020277B3 - Formulacion para la liberacion sostenida de ibuprofen. - Google Patents

Formulacion para la liberacion sostenida de ibuprofen.

Info

Publication number
ES2020277B3
ES2020277B3 ES87306837T ES87306837T ES2020277B3 ES 2020277 B3 ES2020277 B3 ES 2020277B3 ES 87306837 T ES87306837 T ES 87306837T ES 87306837 T ES87306837 T ES 87306837T ES 2020277 B3 ES2020277 B3 ES 2020277B3
Authority
ES
Spain
Prior art keywords
ibuprofen
parts
formulation
sustained release
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87306837T
Other languages
English (en)
Inventor
Brian William Barry
Peter York
Bryan Arthur Mulley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
APS Research Ltd
Original Assignee
APS Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by APS Research Ltd filed Critical APS Research Ltd
Application granted granted Critical
Publication of ES2020277B3 publication Critical patent/ES2020277B3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ES87306837T 1986-08-01 1987-07-31 Formulacion para la liberacion sostenida de ibuprofen. Expired - Lifetime ES2020277B3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868618811A GB8618811D0 (en) 1986-08-01 1986-08-01 Sustained release ibuprofen formulation

Publications (1)

Publication Number Publication Date
ES2020277B3 true ES2020277B3 (es) 1991-08-01

Family

ID=10602077

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87306837T Expired - Lifetime ES2020277B3 (es) 1986-08-01 1987-07-31 Formulacion para la liberacion sostenida de ibuprofen.

Country Status (7)

Country Link
US (1) US4900558A (es)
EP (1) EP0255404B1 (es)
JP (1) JPS63107917A (es)
AT (1) ATE60228T1 (es)
DE (1) DE3767600D1 (es)
ES (1) ES2020277B3 (es)
GB (1) GB8618811D0 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705083D0 (en) * 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
GB8722306D0 (en) * 1987-09-22 1987-10-28 Aps Research Ltd Sustained-release formulation
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
ATE108996T1 (de) * 1988-02-25 1994-08-15 Brocades Pharma Bv Verfahren zur herstellung eines pharmazeutischen granulats.
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
JP2542122B2 (ja) * 1990-04-18 1996-10-09 旭化成工業株式会社 球状核、球形顆粒およびその製造方法
DE69111287T2 (de) * 1990-04-18 1995-12-21 Asahi Chemical Ind Kugelförmige Keimkerne, kugelförmige Granulate sowie Verfahren zu deren Herstellung.
US5213807A (en) * 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5460825A (en) * 1990-05-23 1995-10-24 Mcneil-Ppc, Inc. Taste mask coatings for preparing chewable pharmaceutical tablets
SE9002017D0 (sv) * 1990-06-06 1990-06-06 Kabivitrum Ab Process for manufacture of matrices
WO1992001446A1 (en) * 1990-07-20 1992-02-06 Aps Research Limited Sustained-release formulations
GB9025372D0 (en) * 1990-11-22 1991-01-09 Nat Res Dev Pharmaceutical dosage forms
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
SE9301220D0 (sv) * 1993-04-14 1993-04-14 Kabi Pharmacia Ab Manufacturing matrices
KR950007873A (ko) * 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) * 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
NZ333474A (en) * 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
GB2367002A (en) * 2000-09-25 2002-03-27 British Sugar Plc Coating composition
JP4331930B2 (ja) * 2001-10-17 2009-09-16 武田薬品工業株式会社 酸に不安定な薬物の高含量顆粒
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US10463611B2 (en) 2011-06-08 2019-11-05 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
CN105343033B (zh) * 2015-12-14 2018-03-20 西南药业股份有限公司 一种布洛芬缓释微丸及其制备方法
CN106924205A (zh) * 2015-12-29 2017-07-07 北京阜康仁生物制药科技有限公司 一种含有Baricitinib的缓释制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
US4205060A (en) * 1978-12-20 1980-05-27 Pennwalt Corporation Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4555399A (en) * 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
CH666405A5 (de) * 1985-06-24 1988-07-29 Ciba Geigy Ag Feste, haltbare darreichungsformen mit elastischem filmueberzug.
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules

Also Published As

Publication number Publication date
DE3767600D1 (de) 1991-02-28
EP0255404A1 (en) 1988-02-03
US4900558A (en) 1990-02-13
EP0255404B1 (en) 1991-01-23
ATE60228T1 (de) 1991-02-15
JPS63107917A (ja) 1988-05-12
GB8618811D0 (en) 1986-09-10

Similar Documents

Publication Publication Date Title
ES2020277B3 (es) Formulacion para la liberacion sostenida de ibuprofen.
NO853407L (no) Preparat med kontrollert utskillelse av virkestoff.
ATE109975T1 (de) Pharmazeutische formulierungen mit anhaltender freisetzung.
EP0213083A3 (en) Controlled release tablet
DK0946145T3 (da) Antitussive lægemidler afgivet af ionbytterharpikser
ES2080796T3 (es) Formulaciones de productos farmaceuticos de liberacion prolongada.
NO167183C (no) Fremgangsmaate for fremstilling av et utleveringssystem hvor kjernematerialet beskyttes av et matriks-belegg.
FR2704146B1 (fr) Microcapsules d'acide acétylsalicylique à libération contrôlée.
CA2041774A1 (en) Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
FR2624732B1 (fr) Formulation pharmaceutique a liberation prolongee
ATE173893T1 (de) Matrizen mit verzögerter freisetzung für dentalzwecke
SE8603247D0 (sv) Farmaceutiskt granulat
FI973733A (fi) Farmaseuttinen valmiste ja menetelmä sen valmistamiseksi
DE58901990D1 (de) Feste pharmazeutische retardform.
KR890701502A (ko) 조절된 비료 방출을 위한 설폰화된 중합체 피복물
BR9104402A (pt) Polimero de emulsao diluivel na agua,processo para a preparacao de um polimero de emulsao diluivel na agua,composicao de revestimento aquosa e emprego do polimero
PT86644A (pt) Process for the preparation of dry formulations containing a salt of diclofenac
KR890701013A (ko) 살충제의 설폰화 중합체 피복
FI900017A (fi) Menetelmä tehoainetta alhaisen annoksen kontrolloidusti vapauttavien aspiriinitablettien valmistamiseksi
YU47887B (sh) Postupak za pravljenje čvrstog farmaceutskog preparata za oslobadjanje aktivne supstance
AR240795A2 (es) Nuevos esteres de un derivado del acido vinilciclopropancarboxilico en su forma racemica u opticamente activa y procedimiento de preparacion.
SU1469581A1 (ru) Гербицидный состав
NO892770D0 (no) Fremgangsmaate for bekjempelse av plantesykdommer.
ATE64312T1 (de) Verwendung eines feuerloeschmittles.